References
- World Health Organization. WHO Think-Tank Meeting on Optimizing Antiretroviral Therapy: Meeting Report. March 12, 2020. https://apps.who.int/iris/rest/bitstreams/1327637/retrieve. Accessed March 18, 2021.
- Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–1561.
- World Health Organization. Treat All Implementation; 2019. https://apps.who.int/iris/bitstream/handle/10665/326035/WHO-CDS-HIV-19.20-eng.pdf?ua=1. Accessed March 18, 2021.
- World Health Organization. HIV Drug Resistance Report 2021. https://apps.who.int/iris/handle/10665/349340. Accessed March 18, 2021.
- World Health Organization. Guidelines Consolidated - Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection - Recommandations for a Public Health Approach. Page 31, Chapter 4: Clinical Guidelines: Antiretroviral Therapy, Table 4.11. WHO Definitions of Clinical, Immunological and Virological Failure for the Decision to Switch ART Regimens. 2nd ed.; 2016. https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1. Accessed August 18, 2020.
- World Health Organization. Update of Recommendations on First- and Second-Line Antiretroviral Regimens; 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed August 18, 2020.
- World Health Organization. TLD Up-Take; 2018. http://www.who.int/hiv/pub/arv/treat-all-uptake/en/. Accessed August 18, 2020.
- La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. The Lancet HIV. 2016;3(6):e247-58–e258.
- Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS ONE. 2015;10(2):e0118228.
- Hakim JG, Thompson J, Kityo C, et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018;18(1):47–57.
- World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach; 2021. https://www.who.int/publications/i/item/9789240031593. Accessed September 21, 2021.
- CSLS/MSAS. Normes et protocoles de prise en charge antiretrovirale du VIH et du SIDA; 2016. https://www.afro.who.int/publications. Accessed March 21, 2021.
- MASHM, Malaysia MoH. Malaysian consensus guidelines on antiretroviral therapy 2017; 2017. https://www.moh.gov.my/moh/resources/auto%20download%20images/589d71c4dd799.pdf. Accessed March 21, 2021.
- Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18(1):776–776.
- Censida/Secreteria de Salud. Guia de manejo antirretroviral de las personas con VIH; 2015. www.who.int/hiv/pub/guidelines/mexico_art.pdf. Accessed March 21, 2021.
- Ministerio de Salud, Santiago. Guida Clinica AUGE “Sindrome de la Immunodeficiencia adquirida VIH/SIDA”; 2013. http://www.repositoriodigital.minsal.cl/handle/2015/622?show=full. Access March 21, 2021
- Unitaid and the Clinton Health Access Initiative. Innovative Agreement Launches Affordable, Optimal Second-Line HIV Treatment in Low- and Middle-Income Countries. https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-treatment/#en. Accessed December 8, 2021.
- MSF Access Campaign. Untangling The Web of Antiretroviral Price Reductions 18th edition. 2016. https://msfaccess.org/untangling-web-antiretroviral-price-reductions-18th-edition. Accessed November 1, 2021.
- World Health Organization. Application to Add Darunavir (DRV) to the Essential List of Medicines. https://www.who.int/selection_medicines/committees/expert/20/applications/Darunavir.pdf?ua=1. Accessed March 21, 2021.
- Clinton Health Access Initiative. CHAI HIV Market Report; 2020. https://www.clintonhealthaccess.org/the-state-of-the-hiv-market-in-low-and-middle-income-countries-3/. Accessed March 21, 2021.
- Clinton Health Access Initiative. 2021 HIV Market Report: The State of the HIV Market in Low- and Middle-Income Countries; 2021. https://www.clintonhealthaccess.org/2021-hiv-market-report-the-state-of-the-hiv-market-in-low-and-middle-income-countries/. Accessed December 8, 2021.
- Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253–264.
- Choodari-Oskooei B, Bratton DJ, Gannon MR, Meade AM, Sydes MR, Parmar MK. Adding new experimental arms to randomised clinical trials: Impact on error rates. Clin Trials. 2020;17(3):273–284.
- Bretz F, Gallo P, Maurer W. Adaptive designs: the Swiss Army knife among clinical trial designs? Clin Trials. 2017;14(5):417–424.
- Food and Drug Administration. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, eds. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry; 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry. Accessed March 21, 2021.
- Moore CL, Stohr W, Crook AM, et al. Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet Hiv. 2019;6(5):e334–e340.
- Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol over 10 years at MRC clinical trials unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451–461.
- Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. Aids. 2011;25(7):929–939.
- Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Center for Drug Evaluation and Research; 2015.
- Cook R, Farewell V. Multiplicity considerations in the design and analysis of clinical trials. J R Stat Soc A. 1996;159(1):93–110.
- Schiavone F, Bathia R, Letchemanan K, et al. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials. 2019;20(1):264.
- Keene CM, Griesel R, Zhao Y, et al. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line in adults failing a tenofovir-based first-line regimen: a prospective cohort study. Aids. 2021;35(9):1423–1432.
- Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330–341. Jul 22
- Hill A, McCann K, Chirwa L, Qavi A, Mulenga L. A randomized prospective study evaluating virologic outcomes among patients switching with detectable and undetectable viral loads from efavirenz and nevirapine-based first line ART regimens to DTG regimens in Zambia presented at: AIDS conference; 2020; Virtual. http://programme.aids2020.org/Abstract/Abstract/10841
- Orkin AM, Gill PJ, Ghersi D, et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement. JAMA 2021;326(3):257.
- Mgbako O, Miller EH, Santoro AF, et al. COVID-19, telemedicine, and patient empowerment in HIV care and research. AIDS Behav. 2020;24(7):1990–1993.
- World Health Organization. Disruption in HIV, Hepatitis and STI Services Due to COVID-19. http://covid.hivci.org/dashboard/covid_map.html?r=eyJrIjoiZmI4YmY4ZjktYjUwYi00MDY5LTk2MDEtZTE3YWJkZjYzYzAzIiwidCI6ImViNDJjZGViLWI3YjUtNGE2ZC1iYzFjLWQxZWJjYmZjNDgyZSJ9&pageName=ReportSectionedaf9deae210a0d50226-to-covid-19-november-2020.png?sfvrsn=d45dbe01_5. Accessed December 8, 2021.